Cargando…
BCL2 antagonist of cell death kinases, phosphatases, and ovarian cancer sensitivity to cisplatin
OBJECTIVE: The BCL2 family proteins are critical mediators of cellular apoptosis and, as such, have been implicated as determinants of cancer cell chemo-sensitivity. Recently, it has been demonstrated that the phosphorylation status of the BCL2 antagonist of cell death (BAD) protein may influence ov...
Autores principales: | Bansal, Nisha, Marchion, Douglas C., Bicaku, Elona, Xiong, Yin, Chen, Ning, Stickles, Xiaomang B., Sawah, Entidhar Al, Wenham, Robert M., Apte, Sachin M., Gonzalez-Bosquet, Jesus, Judson, Patricia L., Hakam, Ardeshir, Lancaster, Johnathan M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Gynecologic Oncology and Colposcopy
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280065/ https://www.ncbi.nlm.nih.gov/pubmed/22355465 http://dx.doi.org/10.3802/jgo.2012.23.1.35 |
Ejemplares similares
-
A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth
por: MARCHION, DOUGLAS C., et al.
Publicado: (2013) -
BAD-mediated apoptotic pathway is associated with human cancer development
por: STICKLES, XIAOMANG B, et al.
Publicado: (2015) -
In vitro analysis of ovarian cancer response to cisplatin, carboplatin, and paclitaxel identifies common pathways that are also associated with overall patient survival
por: Bicaku, E, et al.
Publicado: (2012) -
Human cancer cell line microRNAs associated with in vitro sensitivity to paclitaxel
por: CHEN, NING, et al.
Publicado: (2014) -
Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes
por: Saeed-Vafa, Daryoush, et al.
Publicado: (2021)